Credits: Canva
Are you that kind of person who celebrates milestones of your life with getting a tattoo? These milestones could be anything, including the things you achieved, or the things you could not achieve but taught you a lesson. If you are this person, then you must have wondered if you can donate blood with all the tattoos on your body? There are lots of rumors on how can one donate blood, or if at all they are allowed to donate blood. So let's get into its nitty gritty!
As per American Red Cross, in most states, a tattoo is acceptable if the tattoo was applied by a state-regulated entity. Which means the tattoo artist must be licensed and must practice following all the guidelines, using sterile needles and ink that is not reused. The same is the guideline for cosmetic tattoos, which includes microblading of eyebrows. If it is done by a licensed artist in a regulated state, then it is acceptable.
However, if you got your tattoo in a state that does not regulate tattoo facilities, you must wait three months after it was applied.
Similar is the case with body piercings. It has to be done following the regulation, here the key is that the instrument used has to be a single-use equipment and disposable. Which means if you are getting it by a gun, or an earring cassette, they have to be disposable. In case you got your piercing with a reusable gun or a reusable instrument, you will be required to wait for three months.
The reason behind the wait time is associated with the concerns of hepatitis, which could be easily transmitted from donors to patients through transfusion. All blood donations are thus tested for hepatitis B and hepatitis C, with several tests. However, not always are these tests are perfect, thus the three-month period is given.
Donating blood after getting a tattoo can be dangerous as unclean tattoo needle could carry bloodborne viruses, which are hepatitis B, hepatitis C and HIV. In 2020, the Food and Drug Administration (FDA) updated its guideline, making the wait time shorter from one year to three months. This is because if you contract a bloodborne illness, it could be detectable within the period of 3 months.
There are other reasons why you may not be allowed to donate blood. As per the American Red Cross, you are not allowed to donate blood if you have
As per the National Institutes of Health (NIH) Blood Bank, these conditions make you permanently ineligible from donating blood.
While there are certain conditions that makes your permanently ineligible, there are other conditions that makes you temporarily ineligible from donating blood. These include:
Credit: iStock
Long considered a standard tool for assessing body weight, Body Mass Index (BMI) may not be as reliable as once believed. A new study shows that relying on BMI can incorrectly classify people as overweight or obese.
When a team of Italian researchers used the gold standard technique of dual-energy X-ray absorptiometry (DXA) to measure body fat in the general population, they found that the traditional WHO-approved BMI classification system misidentified a significant number of people as having overweight or obesity.
A total of 1,351 adults of mixed gender aged between 18 and 98 years were checked for their body weight using the DXA system.
The results, published in the journal Nutrients, revealed that more than one-third (34 percent) of those with obesity defined by BMI had been misclassified and should be in the overweight category.
For those with an overweight BMI, DXA showed that more than half – 53 percent – had been misclassified – three quarters of those misclassified fall into the normal weight category, while the other quarter should have been classified as having obesity.
The DXA analysis found that the prevalence of overweight and obesity across the cohort was around 37 percent overall (23.4 percent overweight, and 13.2 percent obesity, compared to 26.2 percent and 14.1 percent with BMI).
“In the past few years, there has been a lot of criticism of the BMI system due to its inability to accurately capture body fat percentage or distribution, to correctly categorise weight status based on adiposity,” said Professor Marwan El Ghoch, of the Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Also read: Your BMI Does Not Reflect Your Health: New Study Warns How It Misses A Key Health Aspect
Despite these concerns, BMI as a weight classification system continues to be used in the general population in primary healthcare (i.e., general practitioners) and non-clinical (i.e., policy and health insurance) settings, he added.
The researchers urged revising public health guidelines to consider combining direct body composition or their surrogate measures, such as skinfold measurement or body circumference, with the waist-to-height ratio, with BMI, while assessing weight status in the general population.
In January 2025, India revamped its obesity guidelines, and the new approach focused on abdominal obesity and comorbid diseases, rather than just BMI.
According to the redefining team, it was essential to move beyond BMI-only approaches to tackle the ever-growing number of people related to other major health risks. They stated that while BMI can be a screening tool, obesity must be defined by body fat.
“BMI should be used for screening purposes, but obesity should be confirmed ideally by a measure of body fat wherever feasible, or another measure such as waist circumference, WHR, or Waist-to-height ratio,” Dr. Naval Vikram, Professor of Medicine, at AIIMS, New Delhi, was quoted as saying to IANS at the time.
Also read: 41 million children aged 5-19 living with high BMI in India: Study
It recognizes abdominal fat — closely linked to insulin resistance — as a key factor in the diagnosis. It integrates the presence of comorbidities — such as diabetes and cardiovascular disease — into the diagnostic process.
The revised guidelines also introduce a two-stage classification system, addressing both generalized and abdominal obesity.
Stage 1 Obesity: Increased adiposity (BMI > 23 kg/m²) without apparent effects on organ functions or routine daily activities.
Stage 2 Obesity: Advanced state of obesity with increased BMI more than 23 kg/2, and abdominal adiposity; excess Waist Circumference or Waist-to-Height Ratio.
Credit: Instagram
Amanda Peet, the Hollywood actress known for roles in Something’s Gotta Give, The Whole Nine Yards, and Jack & Jill, recently opened up about her breast cancer diagnosis and how informing her kids about her health became the toughest part for her.
In a New Yorker essay published March 21, the 54-year-old actress announced how a routine scan in August 2025 showed an unusual ultrasound result. Later, a biopsy detected a tumor that “appeared” small.
The Dirty John star found to be in stage 1 of lobular cancer that is “hormone-receptor-positive” and “HER2-negative,” making her “happier than the pre-diagnosis” stage.
It is because Hormone-receptor-positive and HER2-negative cancer is less aggressive and often easier to treat than more aggressive forms of breast cancer.
However, informing her children, Frances, 19, Molly, 15, and Henry, 11, about the cancer was the toughest part for her, and she had to be in the right mindset before sharing the news with them.
“They've been great,” Peet told E! News.
“I definitely had to get myself together before including them. The hard part was realizing that nothing is certain and there was going to be no perfect time to tell them,” she added.
Peet stated that between her diagnosis, she had also been navigating a series of family health crises — with both of her parents' final months in hospice care.
The Your Friends & Neighbors actress, in her essay, also noted that she would “only need a lumpectomy and radiation,” not a double mastectomy.
Also read: Jane Fallon Diagnosed With Breast Cancer, This Is How She Caught It Early
Invasive Lobular Carcinoma (ILC) the second most common form of breast cancer, representing 5 to 15 percent of breast cancer cases.
Rather than a distinct lump, it can appear as a thickening or "fullness" rather than a tumor.
It is often difficult to detect on mammograms, thus MRI or ultrasound are more effective for detection
It is usually hormone receptor-positive.
HR+ and HER2− breast cancer is the most common subtype and is seen among 60–75 per cent of cases.
It is not two different cancers, but rather specific, defining characteristics of the same cancer type (breast cancer). It grows:
According to the Centers for Disease Control and Prevention (CDC), breast cancer screening is a proactive checkup used to find cancer before any physical signs or symptoms appear. While screening doesn’t prevent cancer, its goal is early detection, making the disease much easier to treat.
Since every person’s body and history are different, you and your doctor should engage in informed and shared decision-making. This means discussing the pros and cons to decide together if, and when, screening is right for you.
The US Preventive Services Task Force (a group of national medical experts) provides guidelines based on the latest research:
Average Risk
Women aged 40 to 74 should generally get a mammogram every two years.
High Risk
If you have a family history or other risk factors, your doctor may recommend a different schedule or additional tests.
Credit: iStock
GLP-1 receptor agonists are a modern class of medicines that have changed the treatment of type 2 diabetes and obesity. In simple terms, they help the body respond to food more smartly. After eating, the intestine naturally sends signals that help regulate sugar and appetite levels.
GLP-1 RA medicines imitate this signal. As a result, blood sugar rises less after meals, appetite becomes more controlled, and many people feel full with smaller amounts of food. This is why these medicines are used not only for diabetes, but also for weight reduction in selected people.
These medicines are important because their benefits can go beyond sugar control alone. Studies and current diabetes guidelines show that some GLP-1 RAs can reduce body weight, improve long-term sugar levels, and lower the risk of major heart-related problems in people who have type 2 diabetes and high cardiovascular risk.
Recent guidance also supports their use in some people with chronic kidney disease when cardiovascular risk reduction is an important goal. This does not mean every drug in the group is identical, but it means the class has become medically important for more than just lowering sugar.
For the general public, one important point is that these are not “miracle injections.”
They work best when combined with better food choices, regular walking or exercise, good sleep, and medical follow-up. They are usually started slowly because the commonest side effects are stomach-related, such as nausea, vomiting, constipation, loose motions, or a feeling of fullness.
Not everyone is suitable for them, and the decision depends on a person’s diabetes status, weight, heart or kidney disease, other medicines, and cost. Used properly, GLP-1 RAs are powerful tools that can improve health, but they should always be taken under medical supervision.
So Indian Medical Association (IMA) is planning to seek a mandate restricting prescriptions of GLP-1 drugs to certified endocrinologists/diabetologists or MD general medicine practitioners to curb indiscriminate use and safeguard patient safety as access expands, many media report in August last year about rampant misuse of GLP1 weight loss drugs by cosmetologists, physiotherapists, dermatologists, general MBBS clinicians, and even ayurveda, and other non-modern medicine practitioners.
Many MBBS, physiotherapists, and non-modern medicine practitioners are prescribing GLP1 drugs to people who neither have diabetes nor any comorbidity or acute obesity, but purely for cosmetic reasons to lose some weight that can be otherwise easily done with some lifestyle changes like exercise and diet.
It is a duty of the government to take care of it because there is a lot of misuse and misprescription that needs to be curbed immediately, because these medicines also have side effects.
We will write to the government to take necessary action to stop the misuse of the drug. We will discuss it in our meeting in the first week of April 2026.
© 2024 Bennett, Coleman & Company Limited